Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Micha Levi

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Plos Computational Biology|March 22, 2013
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelLibin Rong, Jeremie Guedj, Harel Dahari, et al.
British Journal of Clinical Pharmacology|August 17, 2019
Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraineJill B Fiedler-Kelly, Orit Cohen-Barak, Denise N Morris, et al.
Frontiers in Pharmacology|January 19, 2024
A minimal PBPK model to accelerate preclinical development of drugs against tuberculosisFederico Reali, Anna Fochesato, Chanchala Kaddi, et al.
BMC Infectious Diseases|December 19, 2024
Replacing serum with dried blood microsampling for pharmacokinetics, viral neutralisation and immunogenicity bioanalysis supporting future paediatric development of RSM01, a candidate respiratory syncytial virus neutralising monoclonal antibodyJoleen T White, Jonne Terstappen, Micha Levi, et al.
Journal of Clinical Pharmacology|April 26, 2020
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab DosingJulie Passarell, David Jaworowicz, Elizabeth Ludwig, et al.
Clinical Pharmacology in Drug Development|March 4, 2022
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of RisperidoneItay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2002
Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneysMicha Levi, James A Knol, William D Ensminger, et al.
BMC Infectious Diseases|December 3, 2024
RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trialAurelio Bonavia, Micha Levi, Harald Rouha, et al.
Cephalalgia : an International Journal of Headache|May 18, 2021
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approachOrit Cohen-Barak, Andrijana Radivojevic, Aksana Jones, et al.
British Journal of Clinical Pharmacology|July 1, 2018
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjectsFrank Schneider, Lavi Erisson, Hooman Beygi, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Plos Computational Biology|March 22, 2013
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelLibin Rong, Jeremie Guedj, Harel Dahari, et al.
British Journal of Clinical Pharmacology|August 17, 2019
Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraineJill B Fiedler-Kelly, Orit Cohen-Barak, Denise N Morris, et al.
Frontiers in Pharmacology|January 19, 2024
A minimal PBPK model to accelerate preclinical development of drugs against tuberculosisFederico Reali, Anna Fochesato, Chanchala Kaddi, et al.
BMC Infectious Diseases|December 19, 2024
Replacing serum with dried blood microsampling for pharmacokinetics, viral neutralisation and immunogenicity bioanalysis supporting future paediatric development of RSM01, a candidate respiratory syncytial virus neutralising monoclonal antibodyJoleen T White, Jonne Terstappen, Micha Levi, et al.
Journal of Clinical Pharmacology|April 26, 2020
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab DosingJulie Passarell, David Jaworowicz, Elizabeth Ludwig, et al.
Clinical Pharmacology in Drug Development|March 4, 2022
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of RisperidoneItay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2002
Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneysMicha Levi, James A Knol, William D Ensminger, et al.
BMC Infectious Diseases|December 3, 2024
RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trialAurelio Bonavia, Micha Levi, Harald Rouha, et al.
Cephalalgia : an International Journal of Headache|May 18, 2021
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approachOrit Cohen-Barak, Andrijana Radivojevic, Aksana Jones, et al.
British Journal of Clinical Pharmacology|July 1, 2018
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjectsFrank Schneider, Lavi Erisson, Hooman Beygi, et al.
Pageof 3